SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Dividend Growth Investing and chit chat. -- Ignore unavailable to you. Want to Upgrade?


To: chowder who wrote (1879)12/30/2021 12:33:55 PM
From: misscbd3 Recommendations

Recommended By
marsdon
red cardinal
rnsmth

  Respond to of 2146
 
Thank you for clarifying your JNJ moves. It helped me. I will stay with my original decision to hold. It is double weight and in the top 10 of my portfolio. If the next dividend increase is commensurate with last year, I see no reason to trim at this point (getting additional income from cefs and other high yielding stocks). I like the safety rating and it seems the new entities may give JNJ the ability to increase its value. Will watch -- and follow your thoughts along those lines.
I stopped adding shares when the yield dropped significantly below 2.7-3+% and instead bot ABBV, AMGN and more recently BMY. Should JNJ's dividend fail to increase as usual -- I would then trim and add to the newbies.



To: chowder who wrote (1879)12/30/2021 5:10:57 PM
From: SeeksQuality3 Recommendations

Recommended By
ddbpaso
red cardinal
rnsmth

  Respond to of 2146
 
Keeping JNJ (our largest position). When it eventually splits, I will reassess each of the pieces, but might very well keep all parts. Might also choose to rebalance between the pieces (the pharma segment is larger than I would normally allow for a stand-alone pharma company).

Remember that this is a voluntary move. I'm not convinced it adds value, but it doesn't damage the businesses significantly either.